Physician profile
Sarah Thomas
NPI 1144298712
$2,024.13
in general payments reported to CMS, 2019-2025
17 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $358 · 2022: $122 · 2023: $49.55 · 2024: $570 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $455.81 | 2019-2025 | Evenity, Tavneos |
| Abbvie INC. | $290.57 | 2020-2025 | |
| Pfizer INC. | $252.45 | 2019-2024 | |
| Genentech USA, INC. | $213.77 | 2019-2025 | Gazyva, Actemra |
| Mallinckrodt Hospital Products INC. | $151.47 | 2023-2024 | Acthar |
| Celgene Corporation | $143.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $137.78 | 2019-2025 | |
| Ucb, INC. | $90.95 | 2024-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $74.58 | 2024-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $47.08 | 2023-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $41.71 | 2024 | Ultomiris, Strensiq |
| Janssen Biotech, INC. | $30.22 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $27.69 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $18.17 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.14 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $16.00 | 2024 | Lupkynis |
| Horizon Therapeutics Plc | $15.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.